Rohan Khera1, Mohammad Hassan Murad2, Apoorva K Chandar3, Parambir S Dulai4, Zhen Wang5, Larry J Prokop6, Rohit Loomba4, Michael Camilleri7, Siddharth Singh8. 1. Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City. 2. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota3Division of Preventive Medicine, Mayo Clinic, Rochester, Minnesota. 3. Division of Gastroenterology and Liver Diseases, Case Western Reserve University, Cleveland, Ohio. 4. Division of Gastroenterology, University of California, San Diego, La Jolla. 5. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota. 6. Department of Library Services, Mayo Clinic, Rochester, Minnesota. 7. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota. 8. Division of Gastroenterology, University of California, San Diego, La Jolla8Division of Biomedical Informatics, University of California, San Diego, La Jolla.
Abstract
IMPORTANCE: Five medications have been approved for the management of obesity, but data on comparative effectiveness are limited. OBJECTIVE: To compare weight loss and adverse events among drug treatments for obesity using a systematic review and network meta-analysis. DATA SOURCES: MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Central from inception to March 23, 2016; clinical trial registries. STUDY SELECTION: Randomized clinical trials conducted among overweight and obese adults treated with US Food and Drug Administration-approved long-term weight loss agents (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, or liraglutide) for at least 1 year compared with another active agent or placebo. DATA EXTRACTION AND SYNTHESIS: Two investigators identified studies and independently abstracted data using a predefined protocol. A Bayesian network meta-analysis was performed and relative ranking of agents was assessed using surface under the cumulative ranking (SUCRA) probabilities. Quality of evidence was assessed using GRADE criteria. MAIN OUTCOMES AND MEASURES: Proportions of patients with at least 5% weight loss and at least 10% weight loss, magnitude of decrease in weight, and discontinuation of therapy because of adverse events at 1 year. RESULTS: Twenty-eight randomized clinical trials with 29 018 patients (median age, 46 years; 74% women; median baseline body weight, 100.5 kg; median baseline body mass index, 36.1) were included. A median 23% of placebo participants had at least 5% weight loss vs 75% of participants taking phentermine-topiramate (odds ratio [OR], 9.22; 95% credible interval [CrI], 6.63-12.85; SUCRA, 0.95), 63% of participants taking liraglutide (OR, 5.54; 95% CrI, 4.16-7.78; SUCRA, 0.83), 55% taking naltrexone-bupropion (OR, 3.96; 95% CrI, 3.03-5.11; SUCRA, 0.60), 49% taking lorcaserin (OR, 3.10; 95% CrI, 2.38-4.05; SUCRA, 0.39), and 44% taking orlistat (OR, 2.70; 95% CrI, 2.34-3.09; SUCRA, 0.22). All active agents were associated with significant excess weight loss compared with placebo at 1 year-phentermine-topiramate, 8.8 kg (95% CrI, -10.20 to -7.42 kg); liraglutide, 5.3 kg (95% CrI, -6.06 to -4.52 kg); naltrexone-bupropion, 5.0 kg (95% CrI, -5.94 to -3.96 kg); lorcaserin, 3.2 kg (95% CrI, -3.97 to -2.46 kg); and orlistat, 2.6 kg (95% CrI, -3.04 to -2.16 kg). Compared with placebo, liraglutide (OR, 2.95; 95% CrI, 2.11-4.23) and naltrexone-bupropion (OR, 2.64; 95% CrI, 2.10-3.35) were associated with the highest odds of adverse event-related treatment discontinuation. High attrition rates (30%-45% in all trials) were associated with lower confidence in estimates. CONCLUSIONS AND RELEVANCE: Among overweight or obese adults, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide, compared with placebo, were each associated with achieving at least 5% weight loss at 52 weeks. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5% weight loss.
IMPORTANCE: Five medications have been approved for the management of obesity, but data on comparative effectiveness are limited. OBJECTIVE: To compare weight loss and adverse events among drug treatments for obesity using a systematic review and network meta-analysis. DATA SOURCES: MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Central from inception to March 23, 2016; clinical trial registries. STUDY SELECTION: Randomized clinical trials conducted among overweight and obese adults treated with US Food and Drug Administration-approved long-term weight loss agents (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, or liraglutide) for at least 1 year compared with another active agent or placebo. DATA EXTRACTION AND SYNTHESIS: Two investigators identified studies and independently abstracted data using a predefined protocol. A Bayesian network meta-analysis was performed and relative ranking of agents was assessed using surface under the cumulative ranking (SUCRA) probabilities. Quality of evidence was assessed using GRADE criteria. MAIN OUTCOMES AND MEASURES: Proportions of patients with at least 5% weight loss and at least 10% weight loss, magnitude of decrease in weight, and discontinuation of therapy because of adverse events at 1 year. RESULTS: Twenty-eight randomized clinical trials with 29 018 patients (median age, 46 years; 74% women; median baseline body weight, 100.5 kg; median baseline body mass index, 36.1) were included. A median 23% of placebo participants had at least 5% weight loss vs 75% of participants taking phentermine-topiramate (odds ratio [OR], 9.22; 95% credible interval [CrI], 6.63-12.85; SUCRA, 0.95), 63% of participants taking liraglutide (OR, 5.54; 95% CrI, 4.16-7.78; SUCRA, 0.83), 55% taking naltrexone-bupropion (OR, 3.96; 95% CrI, 3.03-5.11; SUCRA, 0.60), 49% taking lorcaserin (OR, 3.10; 95% CrI, 2.38-4.05; SUCRA, 0.39), and 44% taking orlistat (OR, 2.70; 95% CrI, 2.34-3.09; SUCRA, 0.22). All active agents were associated with significant excess weight loss compared with placebo at 1 year-phentermine-topiramate, 8.8 kg (95% CrI, -10.20 to -7.42 kg); liraglutide, 5.3 kg (95% CrI, -6.06 to -4.52 kg); naltrexone-bupropion, 5.0 kg (95% CrI, -5.94 to -3.96 kg); lorcaserin, 3.2 kg (95% CrI, -3.97 to -2.46 kg); and orlistat, 2.6 kg (95% CrI, -3.04 to -2.16 kg). Compared with placebo, liraglutide (OR, 2.95; 95% CrI, 2.11-4.23) and naltrexone-bupropion (OR, 2.64; 95% CrI, 2.10-3.35) were associated with the highest odds of adverse event-related treatment discontinuation. High attrition rates (30%-45% in all trials) were associated with lower confidence in estimates. CONCLUSIONS AND RELEVANCE: Among overweight or obese adults, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide, compared with placebo, were each associated with achieving at least 5% weight loss at 52 weeks. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5% weight loss.
Authors: Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich Journal: Lancet Date: 2010-07-29 Impact factor: 79.321
Authors: Patrick M O'Neil; Steven R Smith; Neil J Weissman; Meredith C Fidler; Matilde Sanchez; Jinkun Zhang; Brian Raether; Christen M Anderson; William R Shanahan Journal: Obesity (Silver Spring) Date: 2012-03-16 Impact factor: 5.002
Authors: David E Kelley; George A Bray; F Xavier Pi-Sunyer; Samuel Klein; James Hill; John Miles; Priscilla Hollander Journal: Diabetes Care Date: 2002-06 Impact factor: 19.112
Authors: John M Miles; Lawrence Leiter; Priscilla Hollander; Thomas Wadden; James W Anderson; Michael Doyle; John Foreyt; Louis Aronne; Samuel Klein Journal: Diabetes Care Date: 2002-07 Impact factor: 19.112
Authors: M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield Journal: JAMA Date: 1999-01-20 Impact factor: 56.272
Authors: Xavier Pi-Sunyer; Arne Astrup; Ken Fujioka; Frank Greenway; Alfredo Halpern; Michel Krempf; David C W Lau; Carel W le Roux; Rafael Violante Ortiz; Christine Bjørn Jensen; John P H Wilding Journal: N Engl J Med Date: 2015-07-02 Impact factor: 91.245
Authors: Emily Qualls-Creekmore; Kara L Marlatt; Esther Aarts; Annadora Bruce-Keller; Tim S Church; Karine Clément; Jennifer O Fisher; Penny Gordon-Larsen; Christopher D Morrison; Helen E Raybould; Donna H Ryan; Philip R Schauer; Alan C Spector; Maartje S Spetter; Garret D Stuber; Hans-Rudolf Berthoud; Eric Ravussin Journal: Obesity (Silver Spring) Date: 2020-06-10 Impact factor: 5.002
Authors: Rohan Khera; Ambarish Pandey; Apoorva K Chandar; Mohammad H Murad; Larry J Prokop; Ian J Neeland; Jarett D Berry; Michael Camilleri; Siddharth Singh Journal: Gastroenterology Date: 2018-01-03 Impact factor: 22.682
Authors: Michel Bernier; Dylan Harney; Yen Chin Koay; Antonio Diaz; Abhishek Singh; Devin Wahl; Tamara Pulpitel; Ahmed Ali; Vince Guiterrez; Sarah J Mitchell; Eun-Young Kim; John Mach; Nathan L Price; Miguel A Aon; David G LeCouteur; Victoria C Cogger; Carlos Fernandez-Hernando; John O'Sullivan; Mark Larance; Ana Maria Cuervo; Rafael de Cabo Journal: NPJ Aging Mech Dis Date: 2020-07-21
Authors: Claudia K Fox; Amy C Gross; Eric M Bomberg; Justin R Ryder; Megan M Oberle; Carolyn T Bramante; Aaron S Kelly Journal: Curr Obes Rep Date: 2019-09